

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

Status: RECRUITING

Eligibility Criteria

Sex: MALE

Age: 2 years and over

Healthy Volunteers: This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Male patients
- Diagnosis of XIAP deficiency
- Patients ≥ 2 years of age
- Serum IL-18 ≥ 600 pg/mL (approximately 25% above the lab-defined upper limit of normal of 477 pg/mL)
- Able to take enteral medication

Exclusion Criteria:

- Renal failure requiring dialysis
- Total bilirubin >3 mg/dl and/or SGPT >300 at time of enrollment
- Patients receiving digoxin therapy, who are unable to discontinue treatment due to medical reasons
- Patients receiving fluoroquinolone therapy, who are unable to discontinue treatment due to medical reasons
- Patients who are at risk of pregnancy or fathering a child and are unable to use acceptable methods of birth control during the length of the study
- Patients who have received quercetin or any over the counter anti-oxidant supplementation within last 1 month
- Patients with unstable disease status or other medical issues requiring hospitalization or rapid escalation of medical care
- Participating in another therapeutic study for XIAP deficiency

Conditions & Interventions

Interventions:

DRUG: Quercetin

Conditions:

XIAP Deficiency

More Information

Description:

The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.

Contact(s): Kelly McIntosh - Kelly.mcintosh@cchmc.org

Principal Investigator:

Principal Investigator ID:

Phase: PHASE1

IRB Number:

System ID: NCT07433621

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cchmc.org> to find a Study which is right for you and contact clinicalstudies@cchmc.org if you have questions or need assistance.